Mohammed VI University Hospital of Tangier
Tangier, 90000, Morocco
NCT Number: NCT06674304
Atrial fibrillation is a penalizing disease in several ways: morbidity and mortality, health costs. Several multicenter registries have been published. Until now, no multicenter registry involving several countries has been carried out in Africa. The goal of RIBAT AF Africa is to fill this gap, by recruting patients from twelve african centers. All the centers are a third level Atrial Fibrillation managment facility centers.
After recruitment , a complete clinical assessment with analysis of comorbidities will be a priority of this registry to try to understand the epidemiological profile of atrial fibrillation in Africa. Then, we will proceed to the temporal classification of atrial fibrillation according to the 2024 ESC recommendations (type and thromboembolic risk in particular.).
After this step, the management will be analyzed with three main axes: management of comorbidities, antithrombotic treatment, rhythm and frequency control. Some therapeutic techniques such as ablation of atrial fibrillation were discussed without much detail because many countries do not yet have access to these expensive techniques.
A six-month evaluation is necessary to judge above all the applicability of the measures accessible in all countries and in particular anticoagulant treatment.
All these data will be recorded anonymously and electronically. Each country can have access to its own data anytime. The statistical analysis will be carried out by a team within the University Hospital of Tangier , as well as all IT logistics. This team will also organize electronic monitoring and underlying all abnomalities in CRF.
This study is active but is not currently recruiting participants.
Notify Me18 year and older
All sexes
Observational
Tangier, 90000, Morocco
I. Rational
Atrial fibrillation is a penalizing disease in several ways: morbidity and mortality, health costs. Several multicenter registries have been published. Until now, no multicenter registry involving several countries has been carried out. The goal of RIBAT AF Africa is to fill this gap.
II. Study objectives
III. Study timeline
A six-month evaluation is necessary to judge above all the applicability of the measures accessible in all countries and in particular anticoagulant treatment. The data collection's start estimation is planned for October 2024. Result will be available in October 2025.
IV. Project description
This is a multicentric, prospective and observational study, that will be held simultaneously in 13 african countries. The Moroccan center represented by the Mohammed VI university hospital is the coordinating center as well as the principal investigator (PI) center for this study.
About 3000 patients will be included in the study according to the following criteria:
Inclusion criteria
For the sampling procedures, all patients who meet the inclusion criteria, and followed for management in the study centers, will be included exhaustively until the needed number of subjects is reached.
The 'RIBAT-AFRICA-FA' registry brings together 13 investigating centers in 13 countries; Benin, Cameroun, Egypt, Ethiopia, Gabon, Ivory Coast, Kenya, Mauritania, Morocco, Mali, Niger, Senegal and Tunisia. Each investigating center is located in a university hospital and chaired by a professor of cardiology. In Morocco, the cardiology department of the Mohammed VI University Hospital is the coordinating centre and main investigator. It also coordinates the inclusion of patients in several private cardiology practices in order to ensure that the data is representative of the whole of Morocco.
A Case Report Form (CRF) has been developed by the Moroccan Society of Cardiology, and will be used to collect anamnestic, clinical, exploratory and therapeutic data, as well as six-month outcomes (see appendix).
For each patient included in this study, the CRF will be completed at inclusion, throughout the initial management period and after six months of treatment.
For data collection, an electronic CRF (eCRF) has been created on the CHU Mohammed VI of Tanger's RedCap application. For each investigating center, a private account was created and communicated. In addition, a training session on the use of the eCRF was organized for all investigators.
Throughout the study period, monitoring and data quality management will be carried out by the epidemiology team at CHU Mohammed VI de Tanger.
Supervision and coordination of the registry is the responsibility of the Head of Cardiology at Tangier University Hospital.
Statistical analysis will be performed using IBM SPSS version 25 software. Descriptive data for continuous variables will be presented as means/standard deviation or Median/IQR according to the normality of the distributions, while qualitative variables will be presented as percentages with 95% confidence intervals. Chi-square, Student's t-test or ANOVA will be used within the limits of their respective validity conditions, and where appropriate, non-parametric tests will be used. Multivariate analyses may be indicated, in which case logistic regression and/or the Cox model may be used depending on the model.
V. Ethical Considerations
The sponsor will not have access to the data circuit from collection to statistical analysis and publication.
The data will be stored on a secure server owned by the University Hospital Center (CHU).
No additional paraclinical investigations will be conducted outside of routine care.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: Six month follow up
After inclusion, the investigators carry out a six-month follow-up for the patients. During this prospective follow-up period, the primary judgment criterion that must be documented by the investigators is the occurrence of a complication linked to AF or its medical management. The main complications to be looked for are :
Mohammed VI University Hospital
Other
Acronym: RIBATAFRICA-AF
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04075084
Arrhythmias, Cardiac, Atrial Fibrillation
Adelaide, Australia
View Trial DetailsNCT03940066
Arrhythmias, Cardiac, Atrial Fibrillation
Santander, Spain
View Trial DetailsNCT04732728
Arrhythmias, Cardiac, Atrial Fibrillation
Huntsville, Alabama, United States
View Trial DetailsNCT04198220
Arrhythmias, Cardiac, Atrial Fibrillation
Castrovillari, Italy
View Trial Details